The feasibility of phage therapy for periodontitis

Papers of special note have been highlighted as: • of interest; •• of considerable interest

References

• 1. Tonetti MS, Henry G, Kornman KS. Staging and grading of periodontitis: framework and proposal of a new classification and case definition. J. Periodontol. 89(12), 1475–1475 (2018). •• New classification of periodontitis.
  MedlineGoogle Scholar
• 2. Eke PI, Wei L, Borgnakke WS et al. Periodontitis prevalence in adults ≥65 years of age, in the USA. Periodontology 72(1), 76–95 (2016).
  Google Scholar
• 3. Kassebaum NJ, Bernabé E, Dahiya M, Bhandari B, Murray CJL, Marcenes W. Global burden of severe periodontitis in 1990–2010: a systematic review and meta-regression. J. Dent. Res. 93(11), 1045–1053 (2014).
  Medline CASGoogle Scholar
• 4. Kholy KE, Genco RJ, Van Dyke TE. Oral infections and cardiovascular disease. Trends Endocrinol. Metab. 26(6), 315–321 (2015).
  Medline CASGoogle Scholar
• 5. Katja K, Cathleen H, Müller-Hilke B, Nakata M, Kreikemeyer B. Oral biofilms from symbiotic to pathogenic interactions and associated disease – connection of periodontitis and rheumatic arthritis by peptidylarginine deiminase. Front. Microbiol. 9, 53 (2018).
  MedlineGoogle Scholar
• 6. Börnigen D, Ren B, Pickard R et al. Alterations in oral bacterial communities are associated with risk factors for oral and oropharyngeal cancer. Sci. Rep. 7(1), 17686 (2017).
  MedlineGoogle Scholar
• 7. Marsh PD. Dental plaque: biological significance of a biofilm and community life-style. J. Clin. Periodontol. 32(Suppl. 6), 7–15 (2005). • Classic literature on dental plaque research.
  Medline CASGoogle Scholar
• 8. Velsko IM, Yates JAF, Aron F et al. Microbial differences between dental plaque and historic dental calculus are related to oral biofilm maturation stage. Microbiome 7, 102 (2019).
  MedlineGoogle Scholar
• 9. Velsko IM, Chukkapalli SS, Rivera-Kweh MF et al. Periodontal pathogens invade gingiva and aortic adventitia and elicit inflammasome activation in αvβ6 integrin-deficient mice. Infect. Immun. 83(12), 4582–4593 (2015).
  Medline CASGoogle Scholar
• 10. Drisko CL. Periodontal debridement: still the treatment of choice. J. Evid. Based Dent. 14(s), 33–41 (2014).
  MedlineGoogle Scholar
• 11. [No authors listed]. Parameter on “refractory” periodontitis. J. Periodontol. 71(5-s), 859–860 (2000).
  Google Scholar
• 12. Chiang CP, Hsieh O, Tai WC, Chen YJ, Chang PC. Clinical outcomes of adjunctive indocyanine green-diode lasers therapy for treating refractory periodontitis: a randomized controlled trial with in vitro assessment. J. Formos. Med. Assoc. 119(2), 652–659 (2019).
  MedlineGoogle Scholar
• 13. Habashneh RA, Mashal MA, Khader Y, Qudah R. Clinical and biological effects of adjunctive photodynamic therapy in refractory periodontitis. J. Lasers Med. Sci. 10(2), 139–145 (2019).
  MedlineGoogle Scholar
• 14. Dewhirst FE, Chen T, Izard J et al. The human oral microbiome. J. Bacteriol. 192(19), 5002–5017 (2010).
  Medline CASGoogle Scholar
• 15. He J, Li Y, Cao Y, Xue J, Zhou XD. The oral microbiome diversity and its relation to human diseases. Folia Microbiol. 60(1), 69–80 (2015). •• A general introduction to oral microbiology.
  Medline CASGoogle Scholar
• 16. Edlund A, Santiago-Rodriguez TM, Boehm TK, Pride DT. Bacteriophage and their potential roles in the human oral cavity. J. Oral Microbiol. 7, 27423 (2015).
  MedlineGoogle Scholar
• 17. Lecuit M, Eloit M. The human virome: new tools and concepts. Trends Microbiol. 21(10), 510–515 (2013).
  Medline CASGoogle Scholar
• 18. Bikel S, Valdez-Lara A, Cornejo-Granados F et al. Combining metagenomics, metatranscriptomics and viromics to explore novel microbial interactions: towards a systems-level understanding of human microbiome. Comput. Struct. Biotechnol. J. 13, 390–401 (2015).
  Medline CASGoogle Scholar
• 19. Naidu M, Robles-Sikisaka R, Abeles SR, Boehm TK, Pride DT. Characterization of bacteriophage communities and CRISPR profiles from dental plaque. BMC Microbiol. 14(1), 175 (2014).
  MedlineGoogle Scholar
• 20. Lin DM, Koskella B, Lin HC. Phage therapy: an alternative to antibiotics in the age of multi-drug resistance. World J. Gastrointest. Pharmacol. Ther. 8(3), 162–173 (2017). •• A highly cited review of phages and phage therapy.
  MedlineGoogle Scholar
• 21. Ly M, Abeles SR, Boehm TK et al. Altered oral viral ecology in association with periodontal disease. mBio 5(3), e01133-14 (2014). • A detailed introduction to the study of periodontal-associated viruses.
  MedlineGoogle Scholar
• 22. Lugli GA, Milani C, Turroni F et al. Prophages of the genus Bifidobacterium as modulating agents of the infant gut microbiota. Environ. Microbiol. 18(7), 2196–2213 (2016).
  MedlineGoogle Scholar
• 23. Al-Shayeb B, Sachdeva R, Chen LX et al. Clades of huge phages from across Earth's ecosystems. Nature 578(7795), 425–431 (2020).
  Medline CASGoogle Scholar
• 24. Abedon ST, Kuhl SJ, Blasdel BG, Kutter EM. Phage treatment of human infections. Bacteriophage 1(2), 66–85 (2011).
  MedlineGoogle Scholar
• 25. Ryszard M, Borysowski J, Beata W-D et al. Clinical aspects of phage therapy. Adv. Virus Res. 83, 73–121 (2012). • A comprehensive summary of phage therapy.
  MedlineGoogle Scholar
• 26. Moon JS, Choi EJ, Jeong NN, Sohn JR, Han DW, Oh JW. Research progress of M13 bacteriophage-based biosensors. Nanomaterials 9(10), 1448 (2019).
  CASGoogle Scholar
• 27. Citorik RJ, Mimee M, Lu TK. Sequence-specific antimicrobials using efficiently delivered RNA-guided nucleases. Nature Biotechnol. 32(11), 1141–1145 (2014).
  Medline CASGoogle Scholar
• 28. Lu TK, Collins JJ. Dispersing biofilms with engineered enzymatic bacteriophage. Proc. Natl Acad. Sci. USA 104(27), 11197–11202 (2007).
  Medline CASGoogle Scholar
• 29. Gong P, Cheng M, Li X et al. Characterization of Enterococcus faecium bacteriophage IME-EFm5 and its endolysin LysEFm5. Virology 492, 11–20 (2016).
  Medline CASGoogle Scholar
• 30. Michael L, Dinesh B, Renwick D, Craig B. Potential for bacteriophage endolysins to supplement or replace antibiotics in food production and clinical care. Antibiotics 7(1), 17 (2018).
  Google Scholar
• 31. Jun SY, Jang IJ, Yoon S et al. Pharmacokinetics and tolerance of the phage endolysin-based candidate drug SAL200 after a single intravenous administration among healthy volunteers. Antimicrob. Agents Chemother. 61(6), e02629-16 (2017).
  MedlineGoogle Scholar
• 32. Maszewska A, Zygmunt M, Grzejdziak I, Rozalski A. Use of polyvalent bacteriophages to combat biofilm of Proteus mirabilis causing catheter associated urinary tract infections. J. Appl. Microbiol. 125(5), 1253–1269 (2018).
  Medline CASGoogle Scholar
• 33. Pires DP, Cleto S, Sillankorva S, Azeredo J, TK LU. Genetically engineered phages: a review of advances over the last decade. Microbiol. Mol. Biol. Rev. 80(3), 523–543 (2016).
  Medline CASGoogle Scholar
• 34. Chan BK, Sistrom M, Wertz JE, Kortright KE, Narayan D, Turner PE. Phage selection restores antibiotic sensitivity in MDR Pseudomonas aeruginosa. Sci. Rep. 6, 26717 (2016).
  Medline CASGoogle Scholar
• 35. Sarker SA, Sultana S, Reuteler G et al. Oral phage therapy of acute bacterial diarrhea with two coliphage preparations: a randomized trial in children from Bangladesh. EBioMedicine 4, 124–137 (2016).
  MedlineGoogle Scholar
• 36. Ooi ML, Drilling AJ, Morales S et al. Safety and tolerability of bacteriophage therapy for chronic rhinosinusitis due to Staphylococcus aureus. JAMA Otolaryngol. Head Neck Surg. 145(8), 723–729 (2019).
  MedlineGoogle Scholar
• 37. Loccarrillo C, Abedon ST. Pros and cons of phage therapy. Bacteriophage 1(2), 111–114 (2011).
  MedlineGoogle Scholar
• 38. Pei R, Lamas-Samanamud GR. Inhibition of biofilm formation by T7 bacteriophages producing quorum-quenching enzymes. Appl. Environ. Microbiol. 80(17), 5340–5348 (2014).
  MedlineGoogle Scholar
• 39. Lusiak-Szelachowska M, Weber-Dabrowska B, Gorski A. Bacteriophages and lysins in biofilm control. Virol. Sin. 35(2), 125–133 (2020).
  Medline CASGoogle Scholar
• 40. Pires DP, Oliveira H, Melo Luis DR, Sillankorva S, Azeredo J. Bacteriophage-encoded depolymerases: their diversity and biotechnological applications. Appl. Microbiol. Biotechnol. 100(5), 2141–2151 (2016).
  Medline CASGoogle Scholar
• 41. Lusiak-Szelachowska M, Zaczek M, Weber-Dabrowska B et al. Phage neutralization by sera of patients receiving phage therapy’s. Viral Immunol. 27(6), 295–304 (2014).
  Medline CASGoogle Scholar
• 42. Wang IN. Lysis timing and bacteriophage fitness. Genetics 172(1), 17–26 (2005).
  MedlineGoogle Scholar
• 43. Abdelkader K, Gerstmans H, Saafan A, Dishisha T, Briers Y. The preclinical and clinical progress of bacteriophages and their lytic enzymes: the parts are easier than the whole. Viruses 11(2), 96 (2019).
  CASGoogle Scholar
• 44. Young R, Gill JJ. Phage therapy redux – what is to be done? Science 350(6265), 1163–1164 (2015).
  Medline CASGoogle Scholar
• 45. Debarbieux L, Pirnay JP, Verbeken G et al. A bacteriophage journey at the European Medicines Agency. FEMS Microbiol. Lett. 363(2), fnv225 (2016).
  MedlineGoogle Scholar
• 46. Khalifa L, Brosh Y, Gelman D et al. Targeting Enterococcus faecalis biofilms with phage therapy. Environ. Microbiol. 81(8), 2696–2705 (2015).
  CASGoogle Scholar
• 47. Xiang Y, Li W, Song F et al. Biological characteristics and whole-genome analysis of the Enterococcus faecalis phage PEf771. Can. J. Microbiol. 66(9), 505–520 (2020).
  Medline CASGoogle Scholar
• 48. Bhardwaj SB, Mehta M, Sood S, Sharma J. Isolation of a novel phage and targeting biofilms of drug-resistant oral Enterococci. J. Glob. Infect. Dis. 12(1), 11–15 (2020).
  Medline CASGoogle Scholar
• 49. Fatemeh A, Hosein E, Taghavi ZA et al. Isolation and identification of bacteriophage effective on carbapenemase-resistant Pseudomonas aeruginosa strains. J. Adv. Oral Res. 7(2), 40–44 (2016).
  Google Scholar
• 50. Chou WC, Huang SC, Chiu CH, Chen YYM. YMC-2011, a temperate phage of Streptococcus salivarius 57.I. Appl. Environ. Microbiol. 83(6), e03186 (2017).
  Medline CASGoogle Scholar
• 51. Norris AH: US4957686A (1990).
  Google Scholar
• 52. Dalmasso M, de Haas E, Neve H et al. Isolation of a novel phage with activity against Streptococcus mutans biofilms. PLoS ONE 10(9), e0138651 (2015).
  MedlineGoogle Scholar
• 53. Castillo-Ruiz M, Vines ED, Montt C et al. Isolation of a novel Aggregatibacter actinomycetemcomitans serotype b bacteriophage capable of lysing bacteria within a biofilm. Appl. Environ. Microbiol. 77(9), 3157–3159 (2011).
  Medline CASGoogle Scholar
• 54. Machuca P, Daille L, Vines E, Berrocal L, Bittner M. Isolation of a novel bacteriophage specific for the periodontal pathogen Fusobacterium nucleatum. Appl. Environ. Microbiol. 76(21), 7243–7250 (2010).
  Medline CASGoogle Scholar
• 55. Mitchell HL, Dashper SG, Catmull DV et al. Treponema denticola biofilm-induced expression of a bacteriophage, toxin-antitoxin systems and transposases. Microbiology 156, 774–788 (2010).
  Medline CASGoogle Scholar
• 56. Zhang Y, Shan TL, Li F et al. A novel phage from periodontal pockets associated with chronic periodontitis. Virus Genes 55(3), 381–193 (2019). • Latest research on periodontal-associated phages.
  Medline CASGoogle Scholar